

## **APPLICATION FOR HUMIRA®** (adalimumab)

myAbbVie Assist provides free medicine to qualifying patients. We review all applications on a case-by-case basis. Participation in our program is free; we do not collect any fees from people seeking our assistance.

### CHECKLIST FOR SUBMITTING AN APPLICATION

#### ☐ IF YOU ARE THE PRESCRIBER, COMPLETE PAGE 2

- SECTION 1: Prescriber Information and Shipping Preference
- **SECTION 2:** Patient History, Diagnosis
- **SECTION 3:** Prescription
- **SECTION 4:** Prescriber Certification and Signature

#### IF YOU ARE A PATIENT, COMPLETE PAGE 3. PLEASE READ PAGE 4

- SECTION 5: Patient Information
- SECTION 6: Financial and Medical Information
  - REQUIRED: Please include proof of income for all in household. A copy of your current federal tax return is preferred. If you do not file taxes, alternate documents are acceptable such as W-2 form, Social Security Statement or Pay Stubs.
- **SECTION 7:** Insurance Information
  - If you have Insurance, include front and back copies of all prescription insurance cards.
  - To help us determine your eligibility please also include a detailed list of prescription and medical out of pocket expenses for the household. If you have multiple prescriptions, your pharmacy can print you a list.
- **SECTION 8:** Additional Permission for Program Purposes (Optional)
- **SECTION 9:** Patient Consent and Signature
  - Carefully read the privacy notice and terms of participation in Section 10 on Page 5.
  - Provide your consent for eligibility determination by checking the box in Section 9
  - Confirm your understanding of our privacy policy by providing your signature and date in Section 9.

#### Please keep a copy for your records.

Please do not staple documents together when mailing.

#### FAX OR MAIL THE COMPLETED APPLICATION AND DOCUMENTATION TO THE FOLLOWING

myAbbVie Assist D-617927, AP5 NE 1 N. Waukegan Rd. North Chicago, IL 60064

Phone: 1-800-222-6885 Fax: 1-866-250-2803

Upon review of a completed application, we will notify the prescriber and patient about eligibility. If approved, we will ship the medication to the patient's home unless otherwise indicated on the application. Prior to each subsequent shipment, we will call the patient or prescriber to schedule the next delivery.

Please contact us at 1-800-222-6885 Monday through Friday for additional assistance.

Patient Assistance

APPLICATION FOR HUMIRA® (adalimumab)

PHONE: 1-800-222-6885 FAX: 1-866-250-2803

1 PRESCRIBER INFORMATION • SHIPPIN	NG PREFERENCE					
Prescriber Name:		DO 🗌 Other:_	Rheum 🔲 Derr	m 🔲 Gastro 🔲 Other	:	
Office Name:	C	Office Contact	Name:			
Address:	C	ity/State/Zip:				
NPI or SLN: Phone:			Fax:			
Collaborating MD Name and NPI (if applicable) Name:			NPI:			
Check ONLY if you prefer shipping to the Prescrib						
For additional information on how AbbVie processes y <b>2</b> PATIENT MEDICAL HISTORY	our personal information	on, please vis	it www.abbvie.com/privacy.html.			
			Patient	Cellpl	hone	
Patient's Name:		B:	Phone:	Work	Home	
□ No known allergies □ Allergies (Plea				Patient Weight*		
No other medications     Other Medicat     RHEUMATOID ARTHRITIS     PSORIATIC AR	tions (Please list): _			(if under age 18):		
CROHN'S DISEASE (CD)		<u> </u>	NITIS SUPPURATIVA (HS)*		ITLIII5	
	CERATIVE COLITIS*		IDIOPATHIC ARTHRITIS (JIA)*	OTHER:		
3 RX: MUST BE COMPLETED BY A LICEN	SED PRESCRIBE	R AND FAX	ED DIRECTLY FROM PRESO	CRIBER'S OFFICE		
HUMIRA STARTING THERAPY OPTIONS		QTY	CHOOSE ONE DIRECTION FO			
PSORIASIS / UVEITIS / ADOLESCENT HS (Age 12 & of	lder: 30kg (66 lbs) to < 60					
□ HUMIRA 80 mg/0.8 mL (1) & 40 mg/0.4 mL (2) CIT	RATE FREE PEN	3 PEN KIT	□ Inject 80 mg SQ on Day 1, 40	) mg on Day 8, and	No refills	
□ HUMIRA 40 mg/0.4 mL CITRATE FREE SYRINGE		4 SYRINGES	40 mg every other week			
CROHN'S DISEASE / ULCERATIVE COLITIS / HS			□ Inject 160mg SQ on Day 1 ar	nd 80 mg on Day 15		
<ul> <li>☐ HUMIRA 80 mg/0.8 mL CITRATE FREE PEN</li> <li>☐ HUMIRA 40 mg/0.4 mL CITRATE FREE SYRINGE.</li> </ul>			□ Inject 80mg SQ on Day 1, Da		No refills	
PEDIATRIC CROHN'S DISEASE (Weight: 17kg (37 lbs)		0 STRINGES				
□ HUMIRA 80 mg/0.8 mL & 40 mg/0.4 mL CITRATE F		2 SYRINGE KIT	□ Inject 80 mg SQ on Day 1 an	d 40 mg on Dav 15	No refills	
PEDIATRIC CROHN'S DISEASE (Weight: > 40kg (88 lbs			□ Inject 160mg SQ on Day 1 ar			
□ HUMIRA 80 mg/0.8 mL CITRATE FREE SYRINGE		3 SYRINGE KIT	□ Inject 80mg SQ on Day 1, Da		No refills	
PEDIATRIC ULCERATIVE COLITIS (Weight: 20kg (44lb				ay 2, and Day 10		
□ HUMIRA 40 mg/0.4 mL (4) CITRATE FREE PEN			mg on Day 8 and Day 1	15 No refills		
HUMIRA 40 mg/0.4 mL (4) CITRATE FREE SYRIN				ing on Day o and Day		
PEDIATRIC ULCERATIVE COLITIS (Weight: > 40kg (88			0mg on Day 8 and Day			
□ HUMIRA 80 mg/0.8 mL (4) CITRATE FREE PEN		4 PEN KIT	□ Inject 80mg SQ on Day 1, Da		No refills	
HUMIRA ONGOING THERAPY OPTIONS						
	CHOOSE ONE DIF	RECTION FO	R USE OR WRITE IN BELOW	QUANTITY	REFILLS	
	□ 40 mg SQ EVER	Y OTHER we	ek 🛛 40 mg SQ EVERY week	84 Days Supply–	1 year	
□ HUMIRA 40 mg/0.4mL CITRATE FREE SYRINGE □ HUMIRA 20 mg/0.2mL CITRATE FREE SYRINGE	□ 20 mg SO EV/ER		ek 🛛 20 mg SQ EVERY week	Program Standard	i year	
□ HUMIRA 20 mg/0.2ml CITRATE FREE STRINGE	□ 80 mg SQ EVER			□Other:		
HUMIRA: Please contact myAbbVie Assist for questions	Directions:		procontationa	Qty: Ref	fills:	
PLEASE SUBMIT PRESCRIPTIONS PRESCRIBER PLEASE SIGN AND						
4			COMPUTER-GENERATED IMAGES			
PRESCRIBER				DATE:		
SIGNATURE X AND DATE: Substitution Permit	ted	Dispense	E as Written			
I verify that the information provided is current, complete and accurate to the best of my knowledge. myAbbVie Assist reserves the right to request additional information if needed and to change or discontinue the program at any time, without notice. I shall not seek reimbursement for any medication dispensed hereunder from any government program or third party, including						
change or discontinue the program at any time, without notice. I sh patient, nor will I sell, trade or distribute any such medication. I als						
form, I authorize the program and its representatives to transmit th medication called for herein. I understand that I may not delegate s					nsing of the	

For full Prescribing Information please visit www.rxabbvie.com



# APPLICATION FOR HUMIRA<sup>®</sup> (adalimumab)

#### D-617927, AP5 NE; 1 N. WAUKEGAN RD NORTH CHICAGO, IL 60064 PHONE: 1-800-222-6885 FAX: 1-866-250-2803

5 PATIENT INFORMATION							
Patient Name:							
DOB:		Sex: 🗌 M 🔲 F					
SSN (last f	our digits ONLY):   I  I  I	If you do not have an SSN, check here: 🗌					
Mailing	Address:						
Manng	City/State/Zip:						
Shipping	Address (No P.O. Box):						
Chipping	City/State/Zip:						
Preferred Phone:		Cellphone Work Home					
Alternate Phone:		Cellphone Work Home					
Check the Box for Text Messages* Mobile Phone: Email address:							
* I consent to receive recurring text messages from myAbbVie Assist, including service updates and medication reminders to the above number. Message and data rates may apply. I am not required to consent or provide my consent as a condition of receiving any goods or services. I can reply HELP for help. I can text STOP to unsubscribe any time.							
6 FINA	NCIAL AND MEDICAL INFORMA	ΤΙΟΝ					
Total Incon	ne for the household: \$	Monthly Income Annual Income					
Number in household (including yourself):		Number over 18 yrs old with income:					
Please include financial documentation for <u>everyone in the household.</u> A copy of your current federal tax return is preferred.							
Treating Physician Name:							
Treating Pl	hysician Phone:	Fax:					
**If you have any changes to your medical information please call us at 1-800-222-6885**							
7 ADDITIONAL PERMISSION FOR PURPOSES OF THE PROGRAM (optional)							
I permit myAbbVie Assist to speak with the following person about this application:							
Name	Relationship	Phone Number					

	Patient Assistance		TO BE COMPLET	ED BY PATIENT			
APPLICATION FOR HUMIRA® (adalimumab) D-617927, AP5 NE; 1 N. WAUKEGAN RD NORTH CHICAGO, IL 60064 PHONE: 1-800-222-6885 FAX: 1-866-250-2803							
8 INSURANCE INFORMATION I have no insurance coverage – go to Section 9							
INSURANCE TYP	E: 🗌 Medicar	e 🗌 Medicaid 🗌	Private/Commercial   Othe	er:			
Also include a	a detailed list o		n a front and back copy of all in s a Pharmacy print-out and me our program.				
MEDICAL INSU	RANCE		PRESCRIPTION INSURANCE	E			
Insurance Company:			Insurance Company:				
Insurance. Phone:			Insurance Phone:				
Policy ID #:		Group #:	Policy ID #:	Group #:			
Policyholder Name:		Relationship:	BIN #:	PCN #:			
Do you have sec	ondary insuran	ce? 🗌 Yes 🗌 No	Unsure				
Please provide	your Medicare	Part A Identification	n Number: #				
Value of your assets: \$ Assets include checking and savings accounts, CD's, stocks and bonds, savings bonds, mutual funds, IRAs and other investments, cash at home or anywhere else, and the value of your life insurance policies if turned in for cash right now. Do not include your home, vehicles, burial plots, or personal possessions.							
9 PATIENT CONSENT PLEASE REVIEW HIPAA AUTHORIZATION, PATIENT TERMS OF PARTICIPATION AND PRIVACY NOTICE IN SECTION 10 TO UNDERSTAND HOW WE USE YOUR PERSONAL INFORMATION							
I acknowledge that I have provided accurate and complete information and understand the Patient Terms of Participation in Section 10.							
CHECK THE BOX: I understand that I am providing written instructions to the Program under the Fair Credit Reporting Act authorizing the Program to obtain information about my credit profile from credit reporting agencies or other sources. I authorize the Program to obtain such information solely to determine PAP eligibility.							
PLEASE SIGN       My signature below certifies that I have read, understood and agree to the release of my protected health information pursuant to the HIPAA Authorization in Section 10.         AND DATE:       X							
PATIENT SIGNATURE / LEGAL REPRESENTATIVE (indicate relationship) DATE							

PATIENT INFORMATION

## **APPLICATION FOR HUMIRA®** (adalimumab)

Patient Assistance

> D-617927, AP5 NE • 1 N. WAUKEGAN RD. NORTH CHICAGO, IL 60064 • PHONE: 1-800-222-6885 • FAX: 1-866-250-2803

# 10 HIPAA AUTHORIZATION, PATIENT TERMS OF PARTICIPATION AND PRIVACY NOTICE

## HIPAA AUTHORIZATION

my**AbbVie** 

## Please provide signature in Section 9 of Enrollment Form

I authorize my healthcare providers, pharmacies, insurers, and laboratory testing facilities (my "Healthcare Companies") to disclose information about me, my medical condition, treatment, insurance coverage, and payment information in relation to my use of AbbVie products, to AbbVie to enroll me in and provide me with patient assistance and support for AbbVie products. I understand that information released under this Authorization will no longer be protected by HIPAA. I also understand that if my Healthcare Companies use or disclose my Personal Information for marketing purposes, they may receive financial remuneration.

I understand that I am not required to sign this Authorization and that my Healthcare Companies will not condition my treatment, payment, enrollment, or eligibility for benefits on whether I sign this Authorization. However, I understand that if I do not sign this Authorization, I cannot take part in myAbbVie Assist (should I qualify). This Authorization will expire in 10 years or a shorter period if required by state law, unless I cancel it sooner by calling 1-800-222-6885 or by writing to myAbbVie Assist, D-617927, AP5 NE; 1 N. Waukegan Rd, North Chicago, IL 60064. I understand that cancelling my Authorization will not affect any use of my information that occurred before my request was processed. My**AbbVie** Assist

> D-617927, AP5 NE • 1 N. WAUKEGAN RD. NORTH CHICAGO, IL 60064 PHONE: 1-800-222-6885 • FAX: 1-866-250-2803

# **APPLICATION FOR HUMIRA®** (adalimumab)

## PATIENT TERMS OF PARTICIPATION

myAbbVie Assist provides free medicine to qualifying patients. Participation in our program is free; we do not collect any fees from people seeking our assistance. Medication assistance is dependent on your ability to meet the eligibility criteria for the program as determined by myAbbVie Assist. myAbbVie Assist does not have any obligation to provide the program services to you and is not liable in the provision of these services. The program may be changed or discontinued without notice. You will not seek reimbursement for any products dispensed under the program. You will notify the program if your insurance or financial situation changes. If this application has been completed by a personal representative, the personal representative will provide a copy of this completed application to you.

If you are a member of a Medicare plan including a Medicare Prescription Drug Plan and are qualified for program assistance, you will: (i) be eligible to obtain the medication from the program for a calendar year term (ii) not purchase this medication under your Medicare plan while enrolled in the program; (iii) not submit claims nor seek true out-of-pocket (TrOOP) credit for the medication provided during your enrollment; (iv) provide written notification to your Medicare Prescription Drug Plan, if applicable, that you are receiving your medication at no cost outside of the Medicare Part D benefit.

If you have questions, want to update your information, or terminate your enrollment, please call 1-800-222-6885 or write to us at D-617927, AP5 NE; 1 N. Waukegan Rd, North Chicago, IL 60064.

## PATIENT PRIVACY NOTICE

myAbbVie Assist will use and disclose with authorized third parties your personal information including your financial and health information collected on this enrollment form and through participation in the program for the following purposes:

- (1) To determine your eligibility for the program and to provide you with related services, including transfer to a separate private or public payer program, reimbursement services, services to ship your medication, and other support services.
- (2) To obtain information from your credit profile about your income for the sole purpose of determining eligibility for the program. This notice serves as written instruction under the Fair Credit Reporting Act authorizing myAbbVie Assist to obtain this information.
- (3) To perform research and data analytics to develop and evaluate products, services, materials, and treatments.
- (4) To administer and maintain the quality of the program, including but not limited to case review, compliance checks, audit review and accounting purposes.

For additional information on how AbbVie processes your personal information, please visit www.abbvie.com/privacy.html.